AZN AstraZeneca PLC

175.19USD13304.00 GBp · LSE-2.51%Mkt Cap: 271.71B USDP/E: 24.96

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza,…

Institutional holders20 on file

Key Statistics

Company
Market Cap271.71B USD
Enterprise Value313.27B USD
Revenue (TTM)62.38B USD
Gross Profit48.11B USD
Net Income (TTM)10.22B USD
Revenue/Share40.25 USD
Last Price175.19 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees96.1K
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - General
ISINGB0009895292
Valuation
P/E (Trailing)24.96
P/E (Forward)15.67
PEG1.30
EV/EBITDA11.18
EV/Revenue5.02
P/S3.31
P/B5.34
EPS (TTM)5.27 USD
EPS (Forward)8.49 USD
52W Range
0.000084% of range208.46
52W High208.46 USD
52W Low0.0000 USD
Profitability
Gross Margin81.90%
Oper. Margin25.80%
EBITDA Margin34.11%
Profit Margin17.41%
ROE21.01%
ROA8.96%
ROIC15.24%
ROCE15.97%
Growth
Revenue Growth6.70%
Earnings Growth23.50%
Cash Flow & Leverage
Operating CF14.57B USD
CapEx (TTM)5.91B USD
FCF Margin9.02%
FCF Yield2.07%
Net Debt26.16B USD
Net Debt/EBITDA1.23
Net Debt/FCF4.65
Balance Sheet
Debt/Equity0.60
Current Ratio1.01
Quick Ratio0.79
Book Value/Sh24.90 USD
Cash/Share5.26 USD
Dividends
Fwd Div Rate0.03 USD
Trail. Div Rate0.04 USD
Div. Yield1.75%
5Y Avg Yield2.03%
Payout Ratio45.38%
Ex-Div DateAug 6, 2026
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)216.34 USD
Upside (mean)+23.5%
Target Range161.08 USD – 276.26 USD
161.08+23.5% to mean276.26
# Analysts22
Ownership
Shares Out.1.55B
Float1.54B
Insiders0.05%
Institutions67.09%
Technical
SMA 50167.37 (+4.7%)
SMA 200177.01 (-1.0%)
Beta0.15
S&P 52W Chg12.08%
Avg Vol (30d)2.08M
Avg Vol (10d)2.73M
Technical Indicators
RSI (14)47.8
MACD280.2363
MACD Signal366.3942
MACD Hist.-86.1579
BB Upper192.08 USD
BB Middle179.38 USD
BB Lower166.68 USD
BB Width14.16%
ATR (14)4.113 USD
Vol Ratio (20d)0.89x

About AstraZeneca (LON: AZN)

›

AstraZeneca (LON: AZN) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 96,100 employees.

The shares were at 13304.00 GBp on 19 November 2026, up 6.2% over 52 weeks.

At a market capitalisation of 206.33B GBP, it trades at 25.0 times trailing earnings and 15.7 times forward earnings. The median trailing P/E of its 18 largest Drug Manufacturers - General peers is 25.7, so AZN is valued in line with them. It pays a dividend yielding 1.75% (it pays out 45% of its earnings), against a median of 2.81% among the dividend payers in that peer group.

AstraZeneca reports return on equity of 21.0%, an operating margin of 25.8% and revenue up 6.7% year over year.

Its debt exceeds its cash by 26.16B USD, a debt-to-equity ratio of 0.60. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 22 analysts cover the stock, with an average rating of Buy; their mean price target of 16428.29 GBp is 23.5% above the current price. The next earnings report is expected on 9 February 2027.